CIP2A/p90 Autoantigen Polyclonal Antibody, FITC Conjugated
Product Specifications
Background
Oncoprotein that inhibits PP2A and stabilizes MYC in human malignancies. Promotes anchorage-independent cell growth and tumor formation.
Synonyms
P90; CIP2A; Protein CIP2A; Cancerous inhibitor of PP2A; p90 autoantigen; KIAA1524
Gene ID
57650
Swiss Prot
Q8TCG1
Cellular Locus
Cytoplasm, Cell membrane
Host
Rabbit
Cross Reactivity
Human
Immunogen
601-700/905
Target
CIP2A/p90 Autoantigen
Clonality
Polyclonal
Isotype
IgG
Conjugation
FITC
Source
KLH conjugated synthetic peptide derived from human CIP2A/p90 Autoantigen
Applications
WB
Purification
Purified by Protein A.
Excitation Emission
494nm/518nm
Concentration
1µg/µl
Dilution
WB (1:300-5000)
Buffer
Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Modification
Unmodified
Storage Conditions
Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
Gene ID URL
57650
Predicted Cross Reactivity
Mouse, Rat, Dog, Cow, Rabbit
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
S8022-03B4 250 µg
SULT1A3, Recombinant, Human (Sulfotransferase 1A3/1A4, ST1A3/ST1A4, Aryl Sulfotransferase 1A3/1A4, Catecholamine-sulfating Phenol Sulfotransferase, HAST3, M-PST, Monoamine-sulfating Phenol Sulfotransferase, Placental Estrogen Sulfotransferase, Sulfotransferase, Monoamine-preferring, Thermolabile Phenol Sulfotransferase, TL-PST, STM, SULT1A4) discontinued
Ask
View Details 
